— Published Date: 5/15/2025
Value proposition: Novel analgesic compounds that block CaV3.2 currents in nociceptive dorsal root ganglion neurons in order preemptively treat pain in subjects, unlike other products that are continuously administered post onset of pain.
Technology Description
Resear…
— Technology Description
Researchers at Washington University have developed a range of steroid anesthetic agents that share known neurosteroid structures but are more potent. These compounds share the basic structure of neurosteroids alphaxalone, allopregnanolone, and ent-androsterone, but the stru…
— Technology Description
Researchers at Washington University in St. Louis have developed new compounds that may be used to treat alcohol use disorder (AUD). AUD, a common condition that takes a high personal and public health toll, is characterized by severe problems with drinking- sufferers may co…
— Technology Description
Researchers from Washington University in St. Louis and colleagues have identified ent-allopregnanolone (ent-AlloP) as a potential therapeutic to treat glaucoma. Glaucoma, the leading cause of irreversible blindness, results from damage to the retinal ganglion cells (RGSs) t…
— Neurosteroids are of great interest because of their ability to alter brain function. Compounds of the type disclosed here have potential to be new drugs useful for causing anesthesia and treating depression, anxiety, sleep disorders, seizures.
| Name | # Summaries | Author |
|---|---|---|
| 15 | ||
| 13 | ||
| 15 | ||
| 26 | ||
| 14 | ||
| 14 |
Creating...
